Zacks: Analysts Expect Syros Pharmaceuticals Inc (SYRS) to Post -$0.45 EPS
Wall Street brokerages expect that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will report earnings of ($0.45) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.43) and the lowest estimate coming in at ($0.49). Syros Pharmaceuticals reported earnings of ($0.53) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.1%. The company is expected to report its next quarterly earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.85) per share for the current year, with EPS estimates ranging from ($1.92) to ($1.77). For the next financial year, analysts anticipate that the company will post earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.67). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Friday, August 10th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.07. The business had revenue of $0.38 million during the quarter, compared to the consensus estimate of $1.33 million.
A number of institutional investors and hedge funds have recently modified their holdings of SYRS. Redmile Group LLC increased its stake in Syros Pharmaceuticals by 159.3% during the first quarter. Redmile Group LLC now owns 1,652,240 shares of the company’s stock valued at $21,446,000 after acquiring an additional 1,015,008 shares during the period. BlackRock Inc. increased its stake in Syros Pharmaceuticals by 70.4% during the second quarter. BlackRock Inc. now owns 1,583,631 shares of the company’s stock valued at $16,169,000 after acquiring an additional 654,094 shares during the period. ARK Investment Management LLC increased its stake in Syros Pharmaceuticals by 19.6% during the second quarter. ARK Investment Management LLC now owns 1,799,553 shares of the company’s stock valued at $18,373,000 after acquiring an additional 294,663 shares during the period. Millennium Management LLC increased its stake in Syros Pharmaceuticals by 129.3% during the second quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock valued at $3,834,000 after acquiring an additional 211,696 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in Syros Pharmaceuticals during the second quarter valued at about $1,703,000. Hedge funds and other institutional investors own 60.70% of the company’s stock.
Syros Pharmaceuticals stock opened at $11.76 on Friday. The stock has a market capitalization of $402.51 million, a PE ratio of -5.52 and a beta of -2.06. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $17.89.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Read More: What is a Leveraged Buyout (LBO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.